A Phase II Study of Sorafenib in Combination With Carboplatin and Paclitaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Latest Information Update: 28 May 2024
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Sorafenib (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- 23 May 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 23 May 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
- 21 Feb 2023 Planned End Date changed from 31 May 2023 to 31 Dec 2024.